-
Research and development of new antitumor drugs by Qingdao enterprises is expected to go on the market at the beginning of next year
Time of Update: 2016-09-07
According to the information released by Qingdao science and Technology Bureau, the project of novaferon (English Name: novaferon), an innovative drug developed by Qingdao Jiehua Biotechnology Co., L
-
Eds01 (recombinant human endostatin adenovirus injection), a gene therapy drug for head and neck cancer in Weiyu hospital, was purchased by Guizhou bailing with a price of 50 million yuan
Time of Update: 2016-09-06
Guizhou bailing (hereinafter referred to as "party a") announced on September 5 that it had signed a technology transfer contract with Chengdu endoshi Bioengineering Technology Co., Ltd (hereinafter r
-
Clinical approval of new prostate cancer class 1 drug of Haichuang pharmaceutical
Time of Update: 2016-08-31
Recently, "hc-1119", a new drug substance and preparation project independently developed by Chengdu Haichuang Pharmaceutical Co., Ltd (Haichuang pharmaceutical) for the treatment of prostate cancer c
-
Safety assessment center of Shanghai Institute of drugs has become a landmark achievement of national major new drug creation science and technology project
Time of Update: 2016-08-29
Drag "I thought it was just a small laboratory, but I didn't expect you to do so well!" Recently, three inspectors of FDA (food and Drug Administration) gave a very high appraisal to the research cent
-
New drug R & D is sought after by investors
Time of Update: 2016-08-27
The pursuit of human instinct for the quality and length of life makes the field of health care continue to receive capital attention According to cvsource statistics of China investment group, in 201
-
An article on FDA new drug registration process (NDA)
Time of Update: 2016-08-22
In the United States, it takes about 15 years for a common new compound to apply for marketing from its initial discovery Among them, the time for FDA to review is about 6-10 months The review of new
-
In August, the clinical review of 3 blockbuster new drugs CDE was completed
Time of Update: 2016-08-22
Amxetine hydrochloride enteric coated tablet is a new SNRIs (5-HT and NE reuptake inhibitor) candidate drug, which is mainly used in antidepressant treatment This product was applied for clinical appl
-
New drug R & D has passed a decade of decline
Time of Update: 2016-08-17
Today, NAT Rev Drug discov Publishes an article written by McKinsey analysts to review the changes in the success rate of new drug research and development in the past 20 years (1996-2014) From 1996 t
-
New drug R & D related meeting summary (August September), there will always be one for you!
Time of Update: 2016-08-15
Medical policies have been introduced one after another, relevant regulations have been implemented, and colleagues in the pharmaceutical industry cannot wait to die At present, we have collected rele
-
Stage 3: excellent clinical results, gene therapy for "blindness" may be launched
Time of Update: 2016-08-13
Today, spark therapeutics, a Philadelphia based innovative biotechnology company dedicated to gene therapy, released new data on the continuation of phase 3 clinical trials of its leading candidate pr
-
CDE Drug Evaluation Report in July 2016
Time of Update: 2016-08-13
Hot spot in July, application volume picked up in July, but it was still low, new class 1 drugs declared by new registration classification appeared for the first time in July, advanced biological ant
-
Quinolones market continued to cool down: 3 varieties declined significantly, and the potential of levofloxacin remained
Time of Update: 2016-08-12
Recently, the U.S Food and Drug Administration (FDA) issued a notice, suggesting that when drugs are used to treat acute sinusitis, acute bronchitis and simple urinary tract infection, the risk of ser
-
CDE drug review weekly report (2016.08.01-2016.08.07)
Time of Update: 2016-08-01
Highlights of this week 1 There are still 15 drugs in the review status this week, including 3 3.1 categories (by variety), namely, the sakubitravalin trisodium and pentahydrate tablets (acceptance No
-
Cde2016 June July drug review consultation meeting catalogue
Time of Update: 2016-07-27
In June 2016, the drug review and Consultation Center organized the fifth drug review and consultation meeting in 2016 in Jiangxi Hotel, Beijing from June 15 to June 17, 2016 A total of 151 experts we
-
Announcement of the General Administration of the people's Republic of China on canceling the registration approval documents of 22 products such as azithromycin and sodium chloride injection
Time of Update: 2016-07-25
According to the application of 7 enterprises such as Jichuan Pharmaceutical Group Co., Ltd., the State Food and Drug Administration decided to cancel the registration and approval documents of 22 pro
-
CDE drug review weekly report (July 25, 2016 to July 31, 2016)
Time of Update: 2016-07-25
1 This week (July 17-july 24, 2016), only 11 drugs (according to the acceptance number, the same below) entered the review stage, all of which are 6 types of preparations, and accepted in 2015 This ye
-
Nine varieties of traditional Chinese medicine are approved as the first second level protected varieties of traditional Chinese Medicine
Time of Update: 2016-07-22
On July 22, CFDA official website released the notice of protected varieties of traditional Chinese medicine According to the regulations on the protection of traditional Chinese medicine varieties, i
-
Risperidone upgrading: a global model of improved new drugs
Time of Update: 2016-07-20
Transformation of risperidone: risperidone is a classic old anti schizophrenia drug It has been used in clinic for more than 20 years and is the first in class of the second generation of anti schizop
-
Shanghai Pharmaceutical cooperates with Sichuan University in the research and development of new anti pulmonary fibrosis drugs
Time of Update: 2016-07-20
On July 19, Shanghai Pharmaceutical (02607) launched a cooperation project with Sichuan University to develop a new class 1 anti pulmonary fibrosis drug The cooperation will be carried out between the
-
Four months after the implementation of the registration classification of new chemical drugs, a blowout occurred in the declaration of Class 1 new drugs
Time of Update: 2016-07-19
On March 4 this year, CFDA issued the work plan for the reform of chemical drug registration and classification, which adjusted the registration and classification of chemical drugs, and stipulated th
